Prognostic Biomarkers in Esophageal Squamous Cell Carcinoma

Esophageal squamous cell carcinoma (ESCC) remains a global health challenge owing to its aggressive biology and late presentation. Despite advances in multimodal therapy, five-year survival rates are modest, driving an urgent need for reliable prognostic biomarkers to guide personalised treatment. Investigations to date have focused on systemic inflammatory markers, immunological profiles and metabolic imaging parameters. Ratios derived from routine blood counts—such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR)—have emerged as cost-effective indicators of tumour-host interactions. Concurrently, dynamic changes in immune cell subsets and quantitative imaging metrics hold promise for early assessment of therapeutic response. Integrating these biomarkers into clinical decision-making may improve risk stratification, refine patient selection for neoadjuvant or definitive chemoradiotherapy and ultimately enhance survival outcomes.

Research from Nature Portfolio

Recent studies have reinforced the prognostic value of peripheral blood inflammatory ratios in ESCC patients undergoing definitive chemoradiotherapy. A foundational analysis of over 500 locally advanced cases demonstrated that a high baseline NLR correlates with larger tumour size, advanced TNM stage and poorer performance status. On multivariate evaluation, elevated NLR remained an independent predictor of both progression-free survival and overall survival. Furthermore, serial assessment revealed that patients whose NLR declined after treatment experienced superior outcomes compared with those whose ratio remained high. These findings establish NLR as a simple, widely accessible biomarker for risk stratification and monitoring during chemoradiotherapy.

Prognostic Biomarkers in Esophageal Squamous Cell Carcinoma publication trend

The graph below shows the total number of articles in prognostic biomarkers in esophageal squamous cell carcinoma across all publications each year (not limited to Nature Index journals).

Technical terms

Neutrophil-to-lymphocyte ratio (NLR): The quotient of absolute neutrophil count divided by absolute lymphocyte count, reflecting systemic inflammation and immune status.

Platelet-to-lymphocyte ratio (PLR): The quotient of platelet count divided by lymphocyte count, indicative of thrombo‐inflammatory activity.

Lymphocyte-to-monocyte ratio (LMR): The quotient of lymphocyte count divided by monocyte count, used as a surrogate for tumour-associated macrophage recruitment.

Progression-free survival (PFS): The interval from treatment initiation to documented disease progression or death from any cause.

Overall survival (OS): The interval from treatment initiation to death from any cause, serving as a definitive clinical endpoint.

Definitive chemoradiotherapy (dCRT): Combined modality therapy using chemotherapy and radiotherapy as primary treatment without planned surgery.

Standardised uptake value (SUVmean): A quantitative PET–CT metric representing mean radiotracer uptake in tumour tissue, related to metabolic activity.

References

1. Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma. Frontiers in Immunology (2023).
2. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Scientific Reports (2017).
3. A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR. BMC Cancer (2020).
4. Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy. BioMed Research International (2019).